Old Web
English
Sign In
Acemap
>
Paper
>
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
2020
Andreas Neubauer
Thomas Wiesmann
Claus Vogelmeier
Elisabeth Mack
Chrysanthi Skevaki
Christine Gaik
Christian Keller
Jens Figiel
Kristina Sohlbach
Caroline Rolfes
Harald Renz
Hinnerk Wulf
Andreas Burchert
Keywords:
Cancer research
Acute respiratory distress
Coronavirus disease 2019
ARDS
severe acute respiratory syndrome coronavirus 2
Ruxolitinib
Biology
Immunology
2019 20 coronavirus outbreak
Correction
Source
Cite
Save
Machine Reading By IdeaReader
10
References
12
Citations
NaN
KQI
[]